ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,053Medicare Part D Prescriptions Filled, Including Refills

Rank: 139 out of 1942

$434K Total Retail Price of All Prescriptions

Rank: 169 out of 1942

439 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
64% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Minnesota
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 439 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

4% of this provider’s 439 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

0% of this provider’s 8,542 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 20%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Minnesota
LEVOTHYROXINE SODIUM 419 411 1 3
OMEPRAZOLE 386 361 2 4
FUROSEMIDE 378 371 3 5
WARFARIN SODIUM 352 352 4 11
ATENOLOL 347 328 5 7
SIMVASTATIN 338 329 6 1
DONEPEZIL HCL 215 215 7 30
LISINOPRIL 208 200 8 2
METOPROLOL TARTRATE 186 185 9 9
AMLODIPINE BESYLATE 181 179 10 6
CITALOPRAM HBR 174 172 11 15
TRAMADOL HCL 162 162 12 19
KLOR-CON M20 141 141 13 97
ALBUTEROL SULFATE 140 128 14 152
TRAZODONE HCL 128 128 15 24
NAMENDA 127 127 16 51
ALENDRONATE SODIUM 123 120 17 21
POTASSIUM CHLORIDE 122 121 18 17
GABAPENTIN 119 103 19 16
IPRATROPIUM-ALBUTEROL 113 113 20 134
MIRTAZAPINE 111 109 21 38
QUETIAPINE FUMARATE 111 108 21 61
CARBIDOPA-LEVODOPA 104 101 23 64
POLYETHYLENE GLYCOL 3350 102 95 24 28
CYMBALTA 96 83 25 62
SERTRALINE HCL 87 87 26 20
SPIRONOLACTONE 82 77 27 59
HYDROCHLOROTHIAZIDE 80 80 28 8
TRIAMTERENE-HCTZ 79 67 29 36
LOSARTAN POTASSIUM 73 73 30 18
ATORVASTATIN CALCIUM 72 71 31 14
TAMIFLU 72 68 31 160
CARVEDILOL 66 65 33 39
RISPERIDONE 65 65 34 68
TAMSULOSIN HCL 60 59 35 29
TRIAMCINOLONE ACETONIDE 57 57 36 71
DILTIAZEM 24HR CD 55 55 37 74
LANTUS 54 54 38 49
METFORMIN HCL 53 53 39 10
NYSTOP 52 52 40 128
ESCITALOPRAM OXALATE 52 52 40 127
NYSTATIN 51 43 42 140
BRIMONIDINE TARTRATE 50 50 43 335
METOPROLOL SUCCINATE 50 48 43 13
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 18, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.